Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Why Compounding Access Is Not an Established Path Positioning in the Metabolic Medicine Conversation For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing: Promising mechanism with solid preclinical rationale Early clinical development human efficacy and safety not yet well characterized No legitimate clinical access pathway in the United States as of 2026 Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue Key Takeaways 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide
This needs medical attention, not watchful waiting
Keep out of direct light
But once you add the bacteriostatic water, it should be kept in the fridge
Whether metabolic benefits (improved insulin sensitivity, reduced visceral fat) persist, partially reverse, or fully reverse is unknown
Starting to have much more energy
